Clough Capital Partners’s CRISPR Therapeutics CRSP Stock Holding History

Clough Capital Partners’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-80,800	Closed	-$6.12M	–	120
2021 Q4	$6.12M	Buy	+80,800	New	+$7.06M	0.41%	61
2021 Q3	–	Sell	-242,500	Closed	-$39.3M	–	120
2021 Q2	$39.3M	Buy	242,500 +133,500	+122%	+$16.2M	2.13%	10
2021 Q1	$13.3M	Buy	+109,000	New	+$16.5M	0.59%	58
2020 Q3	–	Sell	-97,300	Closed	-$7.15M	–	128
2020 Q2	$7.15M	Sell	97,300 -109,100	-53%	-$6.38M	0.7%	59
2020 Q1	$8.75M	Buy	+206,400	New	+$10.7M	0.87%	34
2019 Q4	–	Sell	-93,900	Closed	-$3.85M	–	116
2019 Q3	$3.85M	Sell	93,900 -62,100	-40%	-$2.97M	0.32%	58
2019 Q2	$7.35M	Buy	+156,000	New	+$6.23M	0.72%	55

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Clough Capital Partners's CRSP Position: Q2 2026 in Review

Clough Capital Partners increased its CRISPR Therapeutics (CRSP) stake by 298% in Q2 2026, buying an estimated $3.88M and bringing the position to 98,337 shares worth $5.36M. The position accounts for 0.44% of the portfolio, ranked #49.

Clough Capital Partners first reported a position in CRSP in Q4 2016 and has held it in 34 quarters since. The position peaked at $28M in Q2 2021. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Clough Capital Partners held 98,337 shares of CRISPR Therapeutics worth $5.36M as of Q2 2026.
Clough Capital Partners bought 73,652 CRISPR Therapeutics shares in Q2 2026, an estimated $3.88M.
CRISPR Therapeutics made up 0.44% of Clough Capital Partners's portfolio in Q2 2026, its #49 holding.
Clough Capital Partners first reported a position in CRISPR Therapeutics in Q4 2016 and has held it in 34 quarters since.
Clough Capital Partners's CRISPR Therapeutics position peaked at $28M in Q2 2021.
524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Clough Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.